Title
Category
Credits
Event date
Cost
Following a Moving Target: Current and Emerging Strategies for the Prevention and Management of COVID-19 in Patients with Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionAs our understanding of COVID-19 advances, so does our understanding of its impact on the management of multiple sclerosis (MS). In this activity, originally delivered as a live webcast, Drs.
Pathways to Progress: Outlining Key Steps to Diagnosis and Evolving Therapeutic Approaches in CIDP
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionDespite recent advancements in chronic inflammatory demyelinating polyneuropathy (CIDP), significant challenges persist in its accurate diagnosis and optimal treatment. Throughout this program, Drs. Nicholas J. Silvestri, Christyn Edmundson, and Kelly G. Gwathmey will share their expertise, as they guide you through common electrodiagnostic and management pitfalls, outlining evidence-based approaches and drawing from their clinical experience with this rare disease.
Pay It Forward: Bridging the Gaps Between Payers and Providers to Get the Medication Your Patient Needs When They Need It for Narcolepsy and Idiopathic Hypersomnia
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionPatients with narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH) have a diverse range of clinical presentations and therapeutic needs that complicate the process of diagnosis and management. Although significant advancements have been made with the recent approval of several pharmacologic agents specifically indicated for these disorders, the pursuit of insurance authorization for these strategies often leads to obstacles that limit optimal clinical implementation and corresponding patient outcomes.
The Path to Least Resistance: The Emerging Role of Noncovalent BTK Inhibitors in CLL/SLL Across Clinical Practice Settings
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
$0.00
Program DescriptionThe advent of covalent Bruton’s tyrosine kinase inhibitors (cBTKi) (e.g., ibrutinib) in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has significantly enhanced long-term outcomes and quality-of-life for patients as the treatment landscape continues to shift away from traditional chemoimmunotherapy approaches. However, many patients eventually develop treatment resistance, driving disease progression and further limiting therapeutic options.
Transforming the Course of Pompe: Advancements in the Care of Evolving Phenotypes for Patients With Late-Onset Disease
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionNewborn screening (NBS) for Pompe disease (PD) enables earlier diagnosis and life-saving treatments, revealing a higher prevalence than previously known. This increases clinician awareness, crucial for those without NBS access, and extends life expectancy, especially for late-onset PD (LOPD), raising new long-term care questions.
Lost in Transition: Pearls From An Interactive Workshop to Improve the Journey to Adulthood in Spinal Muscular Atrophy
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionHistorically, patients with the most severe forms of spinal muscular atrophy (SMA) were largely unable to survive into adulthood, and those that did often were treated with a palliative approach. However, with the arrival of therapies that can dramatically shift the path of the disease, more and more patients are entering life-long adult care. Unfortunately, as this transition is a new consideration, many clinicians are still learning how to coordinate and manage it appropriately. 
Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis
$0.00
Program DescriptionOver 80% of patients with multiple sclerosis (MS) experience related spasticity. This symptom can be debilitating for both physical and non-physical daily function. Yet, despite the high prevalence and impact of spasticity, a substantial portion of affected patients remain unrecognized and undertreated.
The Hidden Side of Multiple Sclerosis: Harnessing Key Pathologies to Improve Outcomes Across the Multiple Sclerosis Spectrum
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Attendance
$0.00
Program DescriptionThe understanding of MS pathophysiology has rapidly advanced in recent years, prompting reevaluation of concepts that were once considered understood.
Navigating the Clinic: Applying Modern Evidence, Expert Insights, and Practice Simulations to Optimize Idiopathic Hypersomnia Management
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the myCME platform.Program DescriptionIdiopathic hypersomnia (IH) is challenging to diagnose due to poor clinician understanding and its significant clinical overlap with narcolepsy types 1 and 2.
Inside Myasthenia Gravis: Where Providers and Patients Diverge on Defining Treatment Success
$0.00
Program DescriptionThe understanding and prognosis of patients with myasthenia gravis (MG) have made dramatic leaps since the advent of serological evaluation and immunotherapy. In fact, clinicians have become so confident in the ability to diagnose and manage MG that prominent medical organizations commonly boast the ability of these patients to lead “normal lives.” However, studies find that clinician and patient perceptions are often not the same.

Pages